ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, ...
VantAI, a leader in generative AI and drug discovery, today announced the appointment of John Cuozzo, PhD as SVP, Head of Drug Discovery. Cuozzo is an experienced scientific leader with a strong track ...
About Addex: Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel ...
The rapid advancement in photonic integrated circuits (PICs), which combine multiple optical devices and functionalities on a ...
Researchers from the École Polytechnique Fédérale de Lausanne (EPFL) and Shanghai Institute of Microsystem and ...
Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors - - First dose cohort cleared in Phase 1 clinical study of CX-2051, an ...
Encouraging initial signs of efficacy observed for CX-904 in advanced pancreatic cancer, including 2 of 6 patients (33%) with a confirmed partial response and all 6 patients (100%) with disease ...
Treating neuropathic pain and nicotine dependence: Epibatidine derivatives as potential therapeutics
How to treat both neuropathic pain and nicotine dependence using novel epibatidine derivatives as potential therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback